Salarius Pharmaceuticals (SLRX) Stock Price

$0.677 0%

Sign up
to add to portfolio

AI Score

Sell
  • Alternative

    4
  • Fundamental

    1
  • Technical

    3

Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.

Sign up to get access to more historical data and insights on Salarius Pharmaceuticals, AI stock picks, stock alerts and much more.

Sign up

SLRX AI Stock Analysis

AI stock analysis for SLRX is missing at the moment.

Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Salarius Pharmaceuticals (SLRX) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.

Sign up and become a member to get access to AI stock analysis.

Sign up

Salarius Pharmaceuticals (SLRX) Price Prediction

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Salarius Pharmaceuticals (SLRX), currently trading at $0.677, will... Sign up to access price prediction.

Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.

About SLRX

LSE
  • Salarius Pharmaceuticals, Inc.

  • Symbol

    SLRX

  • Market

    NASDAQ

  • Industry

    Biotechnology

  • Market Cap

    1.2M

Similar Stocks

CPRX Catalyst Pharmaceuticals
CPRX
$22.52
1.5%
5
INO Inovio Pharmaceuticals
INO
$1.74
1.2%
1
MRNA Moderna
MRNA
$24.72
1.9%
3
AVXL Anavex Life Sciences
AVXL
$8.95
1.2%
5
BBIO BridgeBio Pharma
BBIO
$33.87
0.1%
4

SLRX Alternative Data

Web Traffic

Salarius Pharmaceuticals receives an estimated 3264 monthly visitors to salariuspharma.com.

  • Web Traffic

    3264

  • Change from Previous Month

    19.3%

  • 3 Month Change

    52%

  • YoY Change

    52%

News Mentions

Salarius Pharmaceuticals was mentioned 0 times in the news yesterday.

  • News Mentions

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

Reddit Mentions

Salarius Pharmaceuticals has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.

  • Reddit Mentions

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

LinkedIn Followers

2,645 are following Salarius Pharmaceuticals on LinkedIn, up by 0.4% over the last month.

  • LinkedIn Followers

    2645

  • Daily Change

    0.1%

  • 1 Month Change

    0.4%

  • 3 Month Change

    5.3%

Job Postings

Salarius Pharmaceuticals currenly has an estimated 0 open job postings.

  • Job Postings

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

LinkedIn Employees

According to LinkedIn, Salarius Pharmaceuticals has 14 employees, up by 16.7% over the last month.

  • LinkedIn Employees

    14

  • Daily Change

    0%

  • 1 Month Change

    16.7%

  • 3 Month Change

    16.7%

Business Outlook

According to employee reviews, the business outlook among employees at Salarius Pharmaceuticals is 100 out of 100 (very bullish).

  • Business Outlook

    100

  • Change from Previous Month

    0%

  • 3 Month Change

    0%

  • YoY Change

    0%

SLRX Financials

SLRX Key Metrics
  • Total Revenue

    $0

  • Net Income

    -$1.5M

  • Earnings per Share

    -$1.52

  • Free cash flow

    -$742.5K

  • EBITDA

    -$1.5M

  • EBITDA Ratio

    0

  • Total Assets

    $3M

SLRX 2-year Revenue & Income
SLRX 2-year Free Cash Flow

SLRX Technicals

SLRX SMA
SLRX RSI

FAQ

What's the current price of Salarius Pharmaceuticals (SLRX) Stock?
The price of an Salarius Pharmaceuticals (SLRX) share is $0.677.

What's the market cap of Salarius Pharmaceuticals?
The current market cap of Salarius Pharmaceuticals is 1.2M.

Should I buy or sell SLRX?
Salarius Pharmaceuticals exhibits several negative alternative data signals, leading us to expect continued underperformance in the coming months. As a result, we maintain a negative outlook on this stock.

Is Salarius Pharmaceuticals a good investment?
Considering the fundamentals, technical analysis, and alternative data insights, it may not be the best time to invest in Salarius Pharmaceuticals stock. There are several bearish signals and market challenges that could negatively impact Salarius Pharmaceuticals' future performance, suggesting that caution should be exercised before making any investment decisions.

Is now a good time to buy Salarius Pharmaceuticals (SLRX) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, it may not be the best time to buy Salarius Pharmaceuticals stock right now, as the outlook appears bearish.

What are some stocks similar to Salarius Pharmaceuticals (SLRX) that investors often compare it to?
Salarius Pharmaceuticals (SLRX) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.

What is the forecast for Salarius Pharmaceuticals' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Salarius Pharmaceuticals' stock price to be around $0.606 in 2026. Starting from the current price of $0.677, this represents a 10.5% change in price, indicating a bearish outlook for the stock.

How to buy Salarius Pharmaceuticals (SLRX) Stock?
Salarius Pharmaceuticals stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Salarius Pharmaceuticals shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.